MCID: FML005
MIFTS: 46

Female Reproductive Endometrioid Cancer

Categories: Cancer diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Female Reproductive Endometrioid Cancer

MalaCards integrated aliases for Female Reproductive Endometrioid Cancer:

Name: Female Reproductive Endometrioid Cancer 11 14 16
Endometrioid Tumor 11 71
Female Reproductive Endometrioid Neoplasm 11
Endometrioid Neoplasm 11

Classifications:



External Ids:

Disease Ontology 11 DOID:3001
NCIt 49 C7113
SNOMED-CT 68 253013001
UMLS 71 C0474809

Summaries for Female Reproductive Endometrioid Cancer

Disease Ontology: 11 A female reproductive organ cancer that is characterized by a resemblance to endometrium.

MalaCards based summary: Female Reproductive Endometrioid Cancer, also known as endometrioid tumor, is related to fallopian tube endometrioid adenocarcinoma and endometrioid ovary carcinoma. An important gene associated with Female Reproductive Endometrioid Cancer is POLE (DNA Polymerase Epsilon, Catalytic Subunit), and among its related pathways/superpathways are Gene expression (Transcription) and ERK Signaling. The drugs Olaparib and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, ovary and lymph node, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Related Diseases for Female Reproductive Endometrioid Cancer

Diseases related to Female Reproductive Endometrioid Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 436)
# Related Disease Score Top Affiliating Genes
1 fallopian tube endometrioid adenocarcinoma 32.0 PMS2 ERBB2 ARID1A
2 endometrioid ovary carcinoma 31.0 TP53 PTEN PPP2R1A POLE PIK3CA MSH6
3 endometriosis 30.3 TP53 PTEN PGR ESR1
4 adenomyosis 29.9 TP53 PTEN KRAS ESR1 CTNNB1
5 endometrial hyperplasia 29.1 TP53 PTEN PGR MSH6 MSH2 MLH1
6 endometrial cancer 28.1 TP53 PTEN PMS2 PIK3R1 PIK3CA PGR
7 ovarian cancer 27.6 TP53 PTEN PPP2R1A PMS2 PIK3R1 PIK3CA
8 ovarian endometrial cancer 11.3
9 high-grade astrocytoma 10.4 TP53 PTEN
10 familial ovarian cancer 10.4 TP53 POLE
11 spindle cell intraocular melanoma 10.4 PMS2 MLH1
12 trachea carcinoma in situ 10.4 KRAS HRAS
13 breast duct papilloma 10.4 PTEN PGR
14 adenofibroma 10.4 TP53 KRAS ARID1A
15 common bile duct neoplasm 10.4 KRAS HRAS
16 esophagus verrucous carcinoma 10.4 TP53 PIK3CA
17 adenosquamous breast carcinoma 10.4 TP53 PGR
18 clear cell adenofibroma 10.3 PIK3CA ARID1A
19 blastoma 10.3 TP53 KRAS HRAS
20 malignant spiradenoma 10.3 TP53 ESR1
21 lung oat cell carcinoma 10.3 TP53 PTEN PIK3CA
22 ampulla of vater benign neoplasm 10.3 KRAS HRAS
23 ovarian clear cell adenocarcinoma 10.3 TP53 PIK3CA ARID1A
24 bladder urachal carcinoma 10.3 KRAS HRAS
25 uterine corpus adenosarcoma 10.3 PGR ESR1
26 endometrial squamous cell carcinoma 10.3 TP53 PGR
27 urachus cancer 10.3 KRAS HRAS
28 esophagus small cell carcinoma 10.3 PIK3CA ERBB2
29 hepatic flexure cancer 10.3 PIK3CA KRAS HRAS
30 liver angiosarcoma 10.3 TP53 KRAS HRAS
31 cystadenofibroma 10.3 TP53 KRAS HRAS
32 adenosquamous lung carcinoma 10.3 KRAS HRAS
33 nodular malignant melanoma 10.3 TP53 PTEN HRAS
34 rectosigmoid junction neoplasm 10.3 MLH1 KRAS
35 large cell carcinoma with rhabdoid phenotype 10.3 TP53 KRAS HRAS
36 sigmoid neoplasm 10.3 MLH1 KRAS HRAS
37 biliary tract benign neoplasm 10.3 TP53 KRAS HRAS
38 keratinizing squamous cell carcinoma 10.3 TP53 PIK3CA HRAS
39 adult cystic nephroma 10.3 PGR ESR1
40 pleomorphic carcinoma 10.3 TP53 KRAS HRAS
41 papillary adenoma 10.3 TP53 KRAS HRAS
42 lipomatosis, multiple 10.3 TP53 PTEN PIK3CA
43 lung carcinoma in situ 10.3 TP53 KRAS HRAS
44 vulva squamous cell carcinoma 10.3 TP53 PIK3CA HRAS
45 appendix disease 10.3 TP53 KRAS HRAS
46 mucinous intrahepatic cholangiocarcinoma 10.3 KRAS HRAS
47 pulmonary adenocarcinoma in situ 10.3 TP53 KRAS HRAS
48 adenocarcinoma in situ 10.3 TP53 KRAS HRAS
49 vagina leiomyosarcoma 10.3 PGR ESR1
50 appendix cancer 10.3 TP53 KRAS HRAS

Graphical network of the top 20 diseases related to Female Reproductive Endometrioid Cancer:



Diseases related to Female Reproductive Endometrioid Cancer

Symptoms & Phenotypes for Female Reproductive Endometrioid Cancer

GenomeRNAi Phenotypes related to Female Reproductive Endometrioid Cancer according to GeneCards Suite gene sharing:

25 (show top 50) (show all 66)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.88 HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.88 HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.88 KRAS
4 Decreased viability GR00106-A-0 10.88 KRAS
5 Decreased viability GR00221-A-1 10.88 ESR1 HRAS KRAS PIK3CA PIK3R1
6 Decreased viability GR00221-A-2 10.88 BRCA1 ESR1 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.88 BRCA1 HRAS PIK3R1
8 Decreased viability GR00221-A-4 10.88 ESR1 PIK3CA
9 Decreased viability GR00301-A 10.88 BRCA1 KRAS
10 Decreased viability GR00381-A-1 10.88 KRAS
11 Decreased viability GR00386-A-1 10.88 ESR1
12 Decreased viability GR00402-S-2 10.88 ESR1 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.81 POLE
14 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.81 PIK3R1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.81 MSH2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.81 KRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.81 POLE
18 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.81 BRCA1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.81 BRCA1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-14 10.81 MSH2 PMS2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.81 PTEN MSH2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.81 PTEN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.81 ERBB2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.81 ERBB2 POLE PTEN ARID1A BRCA1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.81 ARID1A MSH2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.81 PIK3R1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.81 ARID1A
28 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.81 PMS2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.81 ARID1A
30 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.81 HRAS
31 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.81 PMS2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.81 POLE PIK3R1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-204 10.81 BRCA1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.81 ERBB2 POLE PMS2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.81 BRCA1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.81 ARID1A
37 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.81 PTEN MSH2 PIK3R1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.81 KRAS
39 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.81 HRAS
40 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.81 ERBB2 POLE
41 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.81 PIK3R1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.81 PTEN
43 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.81 ARID1A PIK3R1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.81 PMS2
45 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.81 MSH2
46 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.81 ERBB2
47 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.81 ERBB2 POLE PTEN KRAS
48 Increased shRNA abundance (Z-score > 2) GR00366-A-66 10.81 PTEN
49 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.81 ARID1A
50 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.81 HRAS

MGI Mouse Phenotypes related to Female Reproductive Endometrioid Cancer:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.58 ARID1A BRCA1 BRCA2 CTNNB1 ERBB2 ESR1
2 homeostasis/metabolism MP:0005376 10.53 ARID1A BRCA1 BRCA2 CTNNB1 ELAPOR1 ERBB2
3 cellular MP:0005384 10.41 ARID1A BRCA1 BRCA2 CTNNB1 ELAPOR1 ERBB2
4 normal MP:0002873 10.4 ARID1A BRCA1 BRCA2 CTNNB1 ERBB2 ESR1
5 endocrine/exocrine gland MP:0005379 10.4 ARID1A BRCA1 BRCA2 CTNNB1 ERBB2 ESR1
6 nervous system MP:0003631 10.39 ARID1A BRCA1 BRCA2 CTNNB1 ERBB2 ESR1
7 growth/size/body region MP:0005378 10.38 ARID1A BRCA1 BRCA2 CTNNB1 ERBB2 ESR1
8 muscle MP:0005369 10.35 ARID1A BRCA1 CTNNB1 ERBB2 ESR1 HRAS
9 immune system MP:0005387 10.33 ARID1A BRCA1 BRCA2 CTNNB1 ELAPOR1 ESR1
10 digestive/alimentary MP:0005381 10.31 BRCA1 BRCA2 CTNNB1 ERBB2 ESR1 HRAS
11 cardiovascular system MP:0005385 10.27 ARID1A BRCA1 CTNNB1 ELAPOR1 ERBB2 ESR1
12 limbs/digits/tail MP:0005371 10.26 BRCA1 BRCA2 CTNNB1 ELAPOR1 ERBB2 ESR1
13 embryo MP:0005380 10.25 ARID1A BRCA1 BRCA2 CTNNB1 ERBB2 ESR1
14 behavior/neurological MP:0005386 10.25 BRCA1 BRCA2 CTNNB1 ELAPOR1 ERBB2 ESR1
15 no phenotypic analysis MP:0003012 10.19 ARID1A CTNNB1 ESR1 HRAS KRAS PGR
16 reproductive system MP:0005389 10.17 ARID1A BRCA1 BRCA2 CTNNB1 ELAPOR1 ERBB2
17 hematopoietic system MP:0005397 10.09 ARID1A BRCA1 BRCA2 CTNNB1 ELAPOR1 ERBB2
18 skeleton MP:0005390 10.07 ARID1A BRCA1 BRCA2 CTNNB1 ELAPOR1 ERBB2
19 respiratory system MP:0005388 10.02 BRCA1 CTNNB1 ERBB2 ESR1 HRAS KRAS
20 mortality/aging MP:0010768 9.96 ARID1A BRCA1 BRCA2 CTNNB1 ELAPOR1 ERBB2
21 integument MP:0010771 9.53 BRCA1 BRCA2 CTNNB1 ERBB2 ESR1 HRAS

Drugs & Therapeutics for Female Reproductive Endometrioid Cancer

Drugs for Female Reproductive Endometrioid Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Olaparib Approved Phase 3 763113-22-0 23725625
2
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
3
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
4
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
5
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
6
Cediranib Investigational Phase 3 288383-20-0 9933475
7
Maleic acid Experimental, Investigational Phase 3 110-16-7, 110-17-8 444266 444972
8 Poly(ADP-ribose) Polymerase Inhibitors Phase 3
9 Antiviral Agents Phase 3
10 Anti-Infective Agents Phase 3
11 Immunologic Factors Phase 3
12 Antimetabolites Phase 3
13 Immunosuppressive Agents Phase 3
14 Albumin-Bound Paclitaxel Phase 3
15 Antimitotic Agents Phase 3
16 Tubulin Modulators Phase 3
17 Protein Kinase Inhibitors Phase 3
18 Anti-Bacterial Agents Phase 3
19 Antibiotics, Antitubercular Phase 3
20 Liposomal doxorubicin Phase 3
21
Levoleucovorin Approved, Experimental, Investigational Phase 1, Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
22
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
23
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
24
Ipilimumab Approved Phase 2 477202-00-9
25
Tremelimumab Approved, Investigational Phase 2 745013-59-6
26
Acetylcysteine Approved, Investigational Phase 2 616-91-1 581 12035
27
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
29
Cysteine Approved, Nutraceutical Phase 2 52-90-4 594 5862
30
Exatecan Investigational Phase 1, Phase 2 171335-80-1 18546929 151115
31 Folate Phase 1, Phase 2
32 Vitamin B9 Phase 1, Phase 2
33 Vitamin B Complex Phase 1, Phase 2
34 Immunoglobulins, Intravenous Phase 2
35 Angiogenesis Inhibitors Phase 2
36 Immunoglobulins Phase 2
37 Immune Checkpoint Inhibitors Phase 2
38 Antibodies, Monoclonal Phase 2
39 Antibodies Phase 2
40 Antineoplastic Agents, Immunological Phase 2
41 topoisomerase I inhibitors Phase 2
42 Expectorants Phase 2
43 Antidotes Phase 2
44 N-monoacetylcystine Phase 2
45 Respiratory System Agents Phase 2
46 Antioxidants Phase 2
47 Protective Agents Phase 2
48
Valproic acid Approved, Investigational Phase 1 99-66-1 3121
49
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3 3680
50
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 3003 5743

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy Recruiting NCT04575935 Phase 3 Chemotherapy
2 A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
3 Life on the Go 2: Evaluating the Effect of Physical Activity of Patients With Recurrent Ovarian Cancer Using State of the Art Activity Tracking Device Completed NCT03685695 Phase 2
4 Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors Recruiting NCT05001282 Phase 1, Phase 2 ELU001
5 Halting Early Advancement of Residual Disease by Treatment With Bevacizumab and Atezolizumab in Ovarian Cancer Recruiting NCT04510584 Phase 2 Atezolizumab;Bevacizumab
6 A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer Active, not recruiting NCT04034927 Phase 2 Olaparib
7 A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer Active, not recruiting NCT02345265 Phase 2 Cediranib Maleate;Olaparib
8 Evaluation of the Addition of N-Acetylcysteine to Topotecan in the Tumor Microenvironment of Persistent or Recurrent High Grade Endometrioid or Serous Ovarian Carcinoma Terminated NCT02569957 Phase 2 Topotecan Hydrochloride;Acetylcysteine
9 Study of Serum Measured Folate Receptor and Its Induction as a Biomarker in the Diagnosis and Surveillance of Ovarian Carcinoma Completed NCT02520115 Phase 1 Dexamethasone;Valproic Acid
10 Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex) Recruiting NCT02020707 Phase 1 Nab-paclitaxel
11 Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer Active, not recruiting NCT02627443 Phase 1 Berzosertib;Carboplatin;Gemcitabine Hydrochloride
12 A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer Active, not recruiting NCT02111941 Early Phase 1
13 A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy Terminated NCT00899093

Search NIH Clinical Center for Female Reproductive Endometrioid Cancer

Genetic Tests for Female Reproductive Endometrioid Cancer

Anatomical Context for Female Reproductive Endometrioid Cancer

Organs/tissues related to Female Reproductive Endometrioid Cancer:

MalaCards : Endothelial, Ovary, Lymph Node, Uterus, Prostate, Breast

Publications for Female Reproductive Endometrioid Cancer

Articles related to Female Reproductive Endometrioid Cancer:

(show top 50) (show all 59)
# Title Authors PMID Year
1
PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis. 62
35387670 2022
2
Extrauterine Mesonephric-like Neoplasms: Expanding the Morphologic Spectrum. 62
34183523 2022
3
Prognostic factors determining survival after extrapelvic recurrence in endometrioid type endometrial cancer. 62
34794732 2021
4
Role of Imaging in the Management of High-Risk Endometrial Cancer. 62
34900469 2021
5
Primary endometrioid carcinoma of the uterosacral ligament arising from deep infiltrating endometriosis 6 years after bilateral salpingo-oophorectomy due to atypical proliferative endometrioid tumor of the ovary: a rare case report. 62
33308243 2020
6
Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer. 62
33208870 2020
7
Assessment of Preoperative Endometrial Histopathological Sampling as a Predictor of Final Surgical Pathology in Endometrial Cancer. 62
33129220 2020
8
Ovarian Seromucinous Tumors: Pathogenesis, Morphologic Spectrum, and Clinical Issues. 62
32023964 2020
9
Validation of ultrasound strategies to assess tumor extension and to predict high-risk endometrial cancer in women from the prospective IETA (International Endometrial Tumor Analysis)-4 cohort. 62
31225683 2020
10
Omental Micrometastasis in Endometrial Cancer. 62
31340208 2019
11
Sertoliform Endometrioid Tumor of Ovary Presenting as Torsion. 62
27365921 2016
12
Elevated serum progesterone levels in postmenopausal women with mucinous ovarian tumors. 62
26926326 2016
13
Atypical proliferative endometrioid tumor of ovary: Report of a rare case. 62
26497398 2016
14
Association of specific PTEN/10q haplotypes with endometrial cancer phenotypes in African-American and European American women. 62
26026735 2015
15
Significance of p53 expression in background endometrium in endometrial carcinoma. 62
25788166 2015
16
Contrast-enhanced MRI in preoperative assessment of myometrial and cervical invasion, and lymph node metastasis: diagnostic value and error analysis in endometrial carcinoma. 62
25545203 2015
17
Endometrioid adenocarcinoma of the ovary mimicking serous borderline tumor: report of a series of cases. 62
25083962 2014
18
Prediction of staging with preoperative parameters and frozen/section in patients with a preoperative diagnosis of grade 1 endometrioid tumor in endometrial cancer. 62
24790516 2014
19
Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. 62
22653341 2012
20
Differential expression of secreted phosphoprotein 1 in response to estradiol-17β and in ovarian tumors in chickens. 62
22588173 2012
21
[Ovarian preservation during treatment of early stage endometrial cancer]. 62
22198406 2012
22
Clear cell carcinoma of ovary with squamous metaplasia: A unique histopathological observation. 62
22557790 2011
23
Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. 62
21697684 2011
24
The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors). 62
20645105 2011
25
Determination of glycodelin-A expression correlated to grading and staging in ovarian carcinoma tissue. 62
20592354 2010
26
[Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients]. 62
20154485 2010
27
Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors. 62
19269675 2009
28
Comparative proteomic study of two closely related ovarian endometrioid adenocarcinoma cell lines using cIEF fractionation and pathway analysis. 62
19288585 2009
29
Adult extrarenal Wilms tumor of the uterus with teratoid features. 62
18789483 2009
30
Combined large cell neuroendocrine and endometrioid carcinoma of the endometrium. 62
18156975 2008
31
Ovarian sertoli-leydig cell tumors with pseudoendometrioid tubules (pseudoendometrioid sertoli-leydig cell tumors). 62
17414107 2007
32
Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer. 62
16609037 2006
33
Borderline endometrioid tumor arising in a paratubal cyst: a case report. 62
15790473 2005
34
Risk factors for different histological types of ovarian cancer. 62
15228415 2004
35
Ovarian endometrioid tumors of low malignant potential: a clinicopathologic study of 30 cases with comparison to well-differentiated endometrioid adenocarcinoma. 62
12960810 2003
36
Metastatic endocervical adenocarcinoma presenting as a virilizing ovarian mass during pregnancy. 62
12423833 2002
37
Morules with optically clear nuclei in ovarian borderline endometrioid tumor. 62
12588418 2002
38
The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. 62
12060448 2002
39
Endometrioid adenocarcinomas of the uterine corpus in women younger than 50 years of age can be divided into two distinct clinical and pathologic entities based on anatomic location. 62
11745192 2001
40
Cellular apoptosis susceptibility gene expression in endometrial carcinoma: correlation with Bcl-2, Bax, and caspase-3 expression and outcome. 62
11603220 2001
41
Androgen-producing, atypically proliferating endometrioid tumor arising in endometriosis. 62
11332919 2001
42
P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. 62
11328414 2001
43
beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. 62
10433945 1999
44
[Borderline ovarian tumors: a series of 43 patients]. 62
9497606 1997
45
Reliability of tumor typing of endometrial carcinoma in prehysterectomy curettage. 62
7883421 1995
46
Genome scanning detects genetic alterations in human ovarian carcinoma. 62
7981718 1994
47
Proliferative endometrioid tumors and endometrioid tumors of low malignant potential of the ovary. 62
8463037 1993
48
Epithelial ovarian tumors of borderline malignancy: a study of 50 cases. 62
11576258 1992
49
[An immunohistochemical study of ferritin in ovarian epithelial tumours]. 62
1323423 1992
50
An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma. 62
2224770 1990

Variations for Female Reproductive Endometrioid Cancer

Expression for Female Reproductive Endometrioid Cancer

Search GEO for disease gene expression data for Female Reproductive Endometrioid Cancer.

Pathways for Female Reproductive Endometrioid Cancer

Pathways related to Female Reproductive Endometrioid Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.17 TP53 PTEN PPP2R1A PMS2 PGR MSH2
2
Show member pathways
13.93 BRCA1 CTNNB1 ERBB2 ESR1 HRAS KRAS
3 13.88 TP53 PTEN PPP2R1A PIK3R1 PIK3CA PGR
4
Show member pathways
13.81 BRCA1 BRCA2 ERBB2 ESR1 HRAS KRAS
5
Show member pathways
13.74 BRCA1 BRCA2 CTNNB1 ERBB2 ESR1 HRAS
6
Show member pathways
13.64 TP53 PPP2R1A PIK3R1 PIK3CA KRAS HRAS
7
Show member pathways
13.55 TP53 PTEN PIK3R1 PIK3CA MSH6 KRAS
8
Show member pathways
13.5 ERBB2 HRAS KRAS PIK3R1 PPP2R1A PTEN
9
Show member pathways
13.47 CTNNB1 ERBB2 ESR1 HRAS KRAS PIK3CA
10
Show member pathways
13.39 CTNNB1 ERBB2 ESR1 HRAS KRAS PIK3R1
11
Show member pathways
13.31 BRCA1 BRCA2 MLH1 MSH2 MSH6 PMS2
12
Show member pathways
13.19 ERBB2 ESR1 PIK3CA PIK3R1 PPP2R1A PTEN
13
Show member pathways
13.1 PIK3R1 PIK3CA PGR KRAS HRAS ESR1
14
Show member pathways
13.07 TP53 PTEN PPP2R1A PMS2 MSH2 MLH1
15
Show member pathways
13.07 TP53 PTEN PPP2R1A PIK3R1 PIK3CA KRAS
16
Show member pathways
13.04 CTNNB1 HRAS KRAS PIK3R1 PPP2R1A PTEN
17
Show member pathways
13.01 PPP2R1A PIK3R1 PIK3CA KRAS HRAS CTNNB1
18
Show member pathways
13 BRCA1 BRCA2 HRAS KRAS MLH1 MSH2
19
Show member pathways
12.99 PTEN PIK3R1 PIK3CA KRAS HRAS ERBB2
20
Show member pathways
12.95 PTEN PIK3R1 PIK3CA KRAS HRAS
21
Show member pathways
12.93 TP53 PIK3R1 PIK3CA KRAS HRAS
22
Show member pathways
12.93 PIK3R1 PIK3CA KRAS HRAS CTNNB1
23
Show member pathways
12.88 CTNNB1 HRAS KRAS PIK3R1 TP53
24 12.88 PPP2R1A PIK3R1 PIK3CA PGR KRAS HRAS
25
Show member pathways
12.87 POLE PMS2 MSH6 MSH2 MLH1 BRCA2
26
Show member pathways
12.85 PIK3R1 PIK3CA KRAS HRAS ESR1
27 12.81 TP53 PTEN PIK3CA HRAS CTNNB1 BRCA1
28
Show member pathways
12.8 ERBB2 ESR1 PIK3CA PIK3R1 PPP2R1A PTEN
29
Show member pathways
12.78 TP53 PPP2R1A PIK3R1 KRAS HRAS
30
Show member pathways
12.75 HRAS KRAS PIK3CA PIK3R1 PPP2R1A TP53
31
Show member pathways
12.74 POLE PMS2 MSH6 MSH2 MLH1 BRCA2
32
Show member pathways
12.73 BRCA1 BRCA2 ESR1 MSH2 MSH6 POLE
33
Show member pathways
12.71 PPP2R1A PIK3R1 PIK3CA KRAS HRAS
34
Show member pathways
12.68 PPP2R1A PIK3R1 PIK3CA KRAS HRAS
35
Show member pathways
12.66 CTNNB1 ERBB2 HRAS KRAS MSH2 PIK3CA
36 12.63 TP53 PPP2R1A MSH6 MSH2 MLH1 BRCA2
37
Show member pathways
12.61 TP53 PIK3R1 PIK3CA KRAS HRAS ERBB2
38
Show member pathways
12.56 POLE PMS2 MSH6 MSH2 MLH1 BRCA1
39
Show member pathways
12.55 CTNNB1 ERBB2 HRAS KRAS PIK3CA PIK3R1
40
Show member pathways
12.54 PIK3R1 PIK3CA KRAS HRAS ESR1
41
Show member pathways
12.52 PIK3R1 PIK3CA KRAS HRAS ESR1 CTNNB1
42
Show member pathways
12.51 PIK3R1 PIK3CA KRAS HRAS
43
Show member pathways
12.51 PIK3R1 PIK3CA KRAS HRAS
44
Show member pathways
12.51 PIK3R1 PIK3CA KRAS HRAS ERBB2 CTNNB1
45
Show member pathways
12.49 CTNNB1 PIK3CA PIK3R1 PPP2R1A
46
Show member pathways
12.49 TP53 PTEN PIK3R1 PIK3CA HRAS ESR1
47
Show member pathways
12.47 PPP2R1A PGR ESR1 BRCA1
48
Show member pathways
12.46 PIK3R1 PIK3CA HRAS ESR1 ERBB2
49
Show member pathways
12.45 HRAS KRAS PIK3CA PIK3R1 PTEN
50
Show member pathways
12.44 PTEN PIK3R1 PIK3CA HRAS

GO Terms for Female Reproductive Endometrioid Cancer

Cellular components related to Female Reproductive Endometrioid Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromosome GO:0005694 9.86 PPP2R1A MSH6 MSH2 MLH1 BRCA2 BRCA1
2 nuclear ubiquitin ligase complex GO:0000152 9.62 BRCA2 BRCA1
3 MutLalpha complex GO:0032389 9.46 PMS2 MLH1
4 MutSalpha complex GO:0032301 9.26 MSH6 MSH2
5 mismatch repair complex GO:0032300 9.02 PMS2 MSH2 MLH1

Biological processes related to Female Reproductive Endometrioid Cancer according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.29 BRCA1 CTNNB1 ERBB2 HRAS KRAS PGR
2 regulation of cell cycle GO:0051726 10.22 TP53 PTEN MSH2 HRAS BRCA1
3 negative regulation of gene expression GO:0010629 10.17 CTNNB1 ESR1 HRAS PGR PIK3CA TP53
4 double-strand break repair GO:0006302 10.13 TP53 MSH2 BRCA2 BRCA1
5 cellular response to ionizing radiation GO:0071479 10.08 TP53 BRCA2 BRCA1
6 DNA repair GO:0006281 10.07 BRCA1 BRCA2 MLH1 MSH2 MSH6 PMS2
7 fibroblast proliferation GO:0048144 10.05 ESR1 HRAS TP53
8 intrinsic apoptotic signaling pathway GO:0097193 10.04 TP53 MSH6 HRAS
9 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 10.03 TP53 MSH2 BRCA2
10 determination of adult lifespan GO:0008340 10.01 TP53 MSH6 MSH2
11 phosphatidylinositol 3-kinase signaling GO:0014065 10.01 PTEN PIK3R1 PIK3CA ERBB2
12 embryonic organ development GO:0048568 10 TP53 POLE CTNNB1
13 response to X-ray GO:0010165 9.97 TP53 MSH2 BRCA2
14 cellular response to DNA damage stimulus GO:0006974 9.96 TP53 POLE PMS2 MSH6 MSH2 MLH1
15 cell population proliferation GO:0008283 9.95 TP53 PTEN KRAS CTNNB1 BRCA2
16 isotype switching GO:0045190 9.95 MSH6 MSH2 MLH1
17 positive regulation of helicase activity GO:0051096 9.93 MSH6 MSH2
18 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.92 ESR1 TP53
19 mismatch repair GO:0006298 9.92 PMS2 MSH6 MSH2 MLH1
20 cellular response to indole-3-methanol GO:0071681 9.91 BRCA1 CTNNB1
21 positive regulation of isotype switching to IgA isotypes GO:0048298 9.89 MSH2 MLH1
22 chordate embryonic development GO:0043009 9.8 BRCA2 BRCA1
23 maintenance of DNA repeat elements GO:0043570 9.76 MSH6 MSH2
24 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.63 MSH2 MLH1
25 somatic hypermutation of immunoglobulin genes GO:0016446 9.56 PMS2 MSH6 MSH2 MLH1
26 somatic recombination of immunoglobulin gene segments GO:0016447 9.55 MLH1 MSH2 MSH6
27 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.32 PIK3R1 MSH6 MSH2 MLH1 BRCA2 BRCA1

Molecular functions related to Female Reproductive Endometrioid Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 10.44 TP53 POLE PMS2 PGR MSH6 MSH2
2 chromatin binding GO:0003682 10.21 TP53 POLE MSH6 MSH2 MLH1 ESR1
3 nucleotide binding GO:0000166 10.18 POLE PIK3CA MSH6 MSH2 MLH1 KRAS
4 protein C-terminus binding GO:0008022 10.13 MSH2 HRAS ERBB2 CTNNB1 BRCA2
5 single-stranded DNA binding GO:0003697 10.1 BRCA2 MLH1 MSH2 PMS2
6 protein phosphatase binding GO:0019903 10.06 TP53 PIK3R1 ERBB2 CTNNB1
7 ATP-dependent DNA damage sensor activity GO:0140664 9.86 PMS2 MSH6 MSH2 MLH1
8 ErbB-3 class receptor binding GO:0043125 9.84 PIK3R1 ERBB2
9 single guanine insertion binding GO:0032142 9.78 MSH6 MSH2
10 single thymine insertion binding GO:0032143 9.71 MSH2 MSH6
11 guanine/thymine mispair binding GO:0032137 9.63 MLH1 MSH2 MSH6
12 protein serine/threonine kinase activator activity GO:0043539 9.62 PIK3R1 PIK3CA KRAS HRAS
13 enzyme binding GO:0019899 9.58 TP53 PTEN PGR MSH6 MSH2 MLH1
14 mismatched DNA binding GO:0030983 9.43 PMS2 MSH6 MSH2 MLH1

Sources for Female Reproductive Endometrioid Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....